Zacks Research Has Strong Forecast for RDY FY2025 Earnings

Dr. Reddy’s Laboratories Limited (NYSE:RDY) – Investment analysts at Zacks Research lifted their FY2025 earnings per share (EPS) estimates for shares of Dr. Reddy’s Laboratories in a report issued on Tuesday, November 26th. Zacks Research analyst R. Department now expects that the company will earn $0.81 per share for the year, up from their prior forecast of $0.80. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $0.83 per share. Zacks Research also issued estimates for Dr. Reddy’s Laboratories’ Q4 2025 earnings at $0.23 EPS, Q1 2026 earnings at $0.20 EPS, Q2 2026 earnings at $0.21 EPS, Q3 2026 earnings at $0.21 EPS, Q4 2026 earnings at $0.22 EPS, FY2026 earnings at $0.84 EPS, Q1 2027 earnings at $0.18 EPS and Q2 2027 earnings at $0.16 EPS.

RDY has been the topic of a number of other research reports. StockNews.com downgraded Dr. Reddy’s Laboratories from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 13th. Barclays decreased their target price on Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th.

Dr. Reddy’s Laboratories Price Performance

Shares of RDY opened at $14.08 on Thursday. The business’s 50-day moving average is $15.24 and its 200-day moving average is $15.33. Dr. Reddy’s Laboratories has a fifty-two week low of $12.90 and a fifty-two week high of $16.89. The company has a market capitalization of $11.75 billion, a price-to-earnings ratio of 22.49 and a beta of 0.56. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.36.

Institutional Investors Weigh In On Dr. Reddy’s Laboratories

Several hedge funds have recently modified their holdings of the business. Farther Finance Advisors LLC raised its stake in Dr. Reddy’s Laboratories by 43.2% during the third quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock worth $36,000 after acquiring an additional 137 shares in the last quarter. Venturi Wealth Management LLC acquired a new stake in Dr. Reddy’s Laboratories in the 3rd quarter valued at approximately $60,000. Van ECK Associates Corp increased its position in shares of Dr. Reddy’s Laboratories by 64.3% during the 3rd quarter. Van ECK Associates Corp now owns 823 shares of the company’s stock worth $64,000 after purchasing an additional 322 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Dr. Reddy’s Laboratories by 83.2% during the 3rd quarter. GAMMA Investing LLC now owns 1,447 shares of the company’s stock worth $115,000 after purchasing an additional 657 shares during the last quarter. Finally, Glenmede Trust Co. NA bought a new position in shares of Dr. Reddy’s Laboratories during the 3rd quarter worth approximately $207,000. 14.02% of the stock is owned by institutional investors.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.